Intellia is a leading gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system.

from http://intelliatx.com/about-us/overview/

SEC Filings show all

8-K1610-Q610-K1D1S-11

Contact Information

130 Brookline Street, Suite 201
Cambridge, MA 02139
United States

(857) 285-6200

    Overview

    Total FundingEmployeesLast Funding DateStatus
    $85,000,00011-502015-09-01Ipo

    Crunchbase Investment Rounds

    DateAmountRoundValuationLead InvestorOther Investors
    2015-09-01$70,000,000VentureOrbiMedFidelity Management and Research Company, Janus Capital Group, Foresite Capital, Sectoral Asset Management, Atlas Venture, Novartis, EcoR1 Capital
    2014-11-18$15,000,000VentureAtlas Venture, NovartisCaribou Biosciences